MindWalk (HYFT) Q4 2024 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2024 earnings summary
2 Feb, 2026Executive summary
Achieved fifth consecutive quarter of record revenue and record fiscal year revenues, reaching $24.5 million in FY 2024, a 19% year-over-year increase, driven by end-to-end services, AI-driven innovations, and demand for antibody discovery.
Successfully launched LENSai API and Vector Search software, accelerating SaaS commercialization, attracting early access partners, and generating commercial traction and industry recognition.
Expanded European lab facilities and capabilities, fueling growth in antibody discovery, protein production, and fee-for-service work.
Appointed Kristin Taylor as permanent CFO, bringing experience in early-stage and growth companies.
Strategic investments in AI, notably BioStrand's LENSai platform, have begun generating commercial traction and industry recognition.
Financial highlights
Fiscal 2024 revenue reached $24.5 million, up from $20.7 million in FY 2023, outpacing industry averages.
Gross profit margin was 49%, down from 56% last year due to expansion costs and inflation lag; gross profit was $12.1 million, up from $11.6 million.
Operating expenses (excluding impairment) decreased 30% to CAD 26 million, mainly from reduced R&D spend; R&D expenses for FY 2024 were $4.0 million, down from $14.1 million.
Net loss was $27.2 million, including $15 million in non-cash impairments; adjusted net loss (excluding impairments) was $12.1 million, improved from $24.1 million last year.
Cash burn reduced significantly to $4.2 million from $19.8 million in FY 2023; ended year with $3.5 million in unrestricted cash.
Outlook and guidance
Expects continued revenue growth in fiscal 2025, driven by B Cell Select platform, expanded manufacturing, and LENSai software.
Ongoing expansion of laboratory facilities and service offerings, including new equipment and enhanced antibody discovery technologies, is expected to drive growth.
Strategic collaborations and commercialization of LENSai API, including AWS Marketplace rollout, are anticipated to support recurring revenue streams.
Anticipates further revenue from partnerships and fee-for-service projects powered by LENSai.
Focus remains on operational efficiency, financial prudence, and sustained profitability improvements.
Latest events from MindWalk
- AI-driven biologics innovator launches $50M ATM share offering to fund R&D and growth initiatives.HYFT
Registration filing - Revenue up 46%, gross margin at 59%, net loss per share improved, and recurring SaaS revenue booked.HYFT
Q4 2026 - AI-driven life sciences platform seeks up to $250M for R&D and growth, leveraging patented HYFT® technology.HYFT
Registration filing - Q3 revenue up 52% to $4.2M, recurring LensAI contract signed, and cash reached $14.2M.HYFT
Q3 2026 - Resale of up to 15M shares by a major holder may dilute ownership and impact share price.HYFT
Registration Filing - Record revenue, margin gains, and BioStrand growth drive AI-focused momentum.HYFT
Q4 2025 - Gross margin rose to 56% as AI focus grows, but liquidity and Nasdaq risks persist.HYFT
Q2 2025 - Revenue fell 7.5% to CAD 5.3M, net loss widened, and urgent funding needs persist.HYFT
Q1 2025 - $8–$10M deal, 131.8% AI growth, flat revenue, and cost-saving moves drive future profitability.HYFT
Q3 2025